Out of the 341 druggable genes included in the analysis, five encoded the targets of drugs with a lipid-modifying indication (PCSK9, PPARG, PPARA, NPC1L1, and HMGCR) of which NPC1L1, HMGCR, and PCSK9 are targets of drugs used in CHD prevention; and six encoded a protein target of a drug with reported lipid-related adverse effects (ADRB1, TNF, ESR1, FRK, BLK, and DHODH) (Supplementary Data 3). This evidence concerns the gene ESR1 and coronary artery disorder.